Form 10-Q Karyopharm Therapeutics For: Sep 30 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Rhythm Pharmaceuticals (RYTM) Announces IMCIVREE Granted Marketing Authorization by EC for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Setmelanotide now FDA-approved and EC-authorized for Bardet-Biedl syndrome (BBS) EC authorization for BBS makes Rhythm eligible to receive second $37.5M tranche under Revenue Interest Agreement
– Achieved First Quarter 2022 Net Revenues of $47.7 Million, Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from Partners – –.